A recently published phase I clinical trial shows that an oncolytic vaccinia virus, JX-594, can reach and infect tumors following a single intravenous infusion, despite the barriers to systemic virus spread.1 Direct evidence of virus localization in tumors, along with a portfolio of supportive data, suggests that virus can also replicate selectively in tumors. These data come extremely close to validating the basic principles underlying the development of replicating viruses for cancer therapy.2,3
No takes yet. Share an insight, caveat, or question.
Vile et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: